Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTXNASDAQ:BIORNASDAQ:JAGXNASDAQ:ONCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$1.23-1.9%$1.62$1.11▼$27,200.00$2.60M1.49909,964 shs349,305 shsBIORBiora Therapeutics$0.15+6.5%$0.14$0.15▼$7.90$660K1.1280,734 shs16,292 shsJAGXJaguar Animal Health$2.57-0.2%$5.41$2.43▼$110.75$2.62M0.5654,173 shs17,887 shsONCOOnconetix$4.65-4.2%$5.82$3.82▼$1,190.00$2.46M3.38114,208 shs63,918 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt0.00%-7.82%-20.39%-67.04%-99.99%BIORBiora Therapeutics0.00%0.00%+7.44%+24.70%-97.84%JAGXJaguar Animal Health0.00%+2.60%-36.82%-46.45%-97.14%ONCOOnconetix0.00%-3.83%-26.25%-24.10%-99.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADTXAditxtN/AN/AN/AN/AN/AN/AN/AN/ABIORBiora TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar Animal Health1.8429 of 5 stars3.53.00.00.00.90.00.6ONCOOnconetix0.2899 of 5 stars0.04.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 0.00N/AN/AN/ABIORBiora Therapeutics 3.00Buy$23.0015,664.22% UpsideJAGXJaguar Animal Health 3.00Buy$60.002,239.18% UpsideONCOOnconetix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BIOR, ADTX, JAGX, and ONCO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$130K19.99N/AN/A($1.52) per share-0.81BIORBiora Therapeutics$892K0.74N/AN/A($36.43) per share0.00JAGXJaguar Animal Health$11.69M0.22N/AN/A$12.29 per share0.21ONCOOnconetix$2.52M0.98N/AN/A$11.22 per share0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$34.45MN/A0.00∞N/A-46,082.47%-389.10%-84.71%8/18/2025 (Estimated)BIORBiora Therapeutics-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%8/11/2025 (Estimated)JAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)ONCOOnconetix-$58.69MN/A0.00∞N/A-2,913.71%-514.04%-75.82%8/27/2025 (Estimated)Latest BIOR, ADTX, JAGX, and ONCO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q1 2025ONCOOnconetixN/A$21.25N/A-$0.53N/A$0.10 million5/15/2025Q1 2025ADTXAditxt-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 million5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/ABIORBiora TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.080.08BIORBiora TherapeuticsN/A0.050.05JAGXJaguar Animal Health22.201.080.70ONCOOnconetixN/A0.170.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%BIORBiora Therapeutics43.74%JAGXJaguar Animal Health12.04%ONCOOnconetix23.89%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%BIORBiora Therapeutics51.08%JAGXJaguar Animal Health0.38%ONCOOnconetix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt602.12 million2.12 millionNo DataBIORBiora Therapeutics1204.52 million2.21 millionOptionableJAGXJaguar Animal Health501.02 million1.01 millionNo DataONCOOnconetix12530,000516,000N/ABIOR, ADTX, JAGX, and ONCO HeadlinesRecent News About These CompaniesOnconetix, Inc. Announces Positive Decision by Nasdaq Hearings PanelJune 16, 2025 | globenewswire.comOnconetix (NASDAQ:ONCO) Trading Down 24.9% - Should You Sell?June 14, 2025 | marketbeat.comOnconetix (NASDAQ:ONCO) Rating Increased to Hold at Wall Street ZenJune 14, 2025 | marketbeat.comOnconetix, Inc. (NASDAQ:ONCO) Short Interest UpdateJune 13, 2025 | marketbeat.comOnconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by StockholdersJune 13, 2025 | nasdaq.comOnconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of StockholdersJune 11, 2025 | globenewswire.comOnconetix faces potential Nasdaq delisting over filing delaysMay 24, 2025 | investing.comOnconetix receives additional delisting notice from NasdaqMay 23, 2025 | finance.yahoo.comOnco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision OncologyMay 22, 2025 | accessnewswire.comAOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqMay 22, 2025 | globenewswire.comOnco-Innovations Uplists to Cboe CanadaMay 22, 2025 | businesswire.comOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqApril 30, 2025 | globenewswire.comOnconetix faces third delisting threat since 2022 IPOApril 21, 2025 | bizjournals.comOnco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP TechnologyApril 17, 2025 | accessnewswire.comAOnco-Innovations Announces Private PlacementApril 16, 2025 | accessnewswire.comAOnconetix Inks Letter Of Intent For Potential Business Combination With OcuvexApril 10, 2025 | nasdaq.comFive things you need to know today, and calming irrational fearsApril 9, 2025 | bizjournals.comOnconetix signs non-binding LOI for potential combination with OcuvexApril 9, 2025 | markets.businessinsider.comCincinnati's Onconetix pursuing merger deal with drug development firmApril 8, 2025 | bizjournals.comOnconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.April 8, 2025 | markets.businessinsider.com🌱 Cincinnati's arena debate heats upApril 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIOR, ADTX, JAGX, and ONCO Company DescriptionsAditxt NASDAQ:ADTX$1.23 -0.02 (-1.92%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$1.19 -0.04 (-2.94%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Biora Therapeutics NASDAQ:BIOR$0.15 +0.01 (+6.50%) As of 06/13/2025Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Jaguar Animal Health NASDAQ:JAGX$2.56 -0.01 (-0.19%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$2.60 +0.04 (+1.52%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Onconetix NASDAQ:ONCO$4.64 -0.21 (-4.23%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$4.55 -0.09 (-2.05%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
